Abstracts tagged "Cardiovascular disease"

Abstract Number: 115 • 2015 ACR/ARHP Annual Meeting
Validation of a Large Rheumatoid Arthritis Cohort and Preventive Health Screening
Michael Grasso¹, Dana Direnzo², Yelena Yesha³, Naphtali Rishe⁴ and Amanda Niskar⁵, ¹Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD, ²Internal Medicine, University of Maryland Medical Center, Baltimore, MD, ³Computer Science and Electrical Engineering, Professor, Baltimore, MD, ⁴Computer Science, Florida International University, Miami, FL, ⁵1330 West Peachtree Street NW, Arthritis Foundation, Atlanta, GA
Background/Purpose: We extracted a large cohort of rheumatoid arthritis (RA) patients, on which we plan to apply big data analytics for earlier diagnosis of RA.…
Abstract Number: 1057 • 2015 ACR/ARHP Annual Meeting
Are Ankylosing Spondylitis, Psoriatic Arthritis and Undifferentiated Spondylarthritis Associated with an Increased Risk of Cardiovascular Disease?
Karin Bengtsson¹, Helena Forsblad-d'Elia², Elisabeth Lie¹, Eva Klingberg¹, Mats Dehlin¹, Sofia Exarchou³, Ulf Lindström¹, Johan Askling⁴ and Lennart TH Jacobsson¹, ¹Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ²Departments of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, ³Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴Clinical Epidemiology Unit and Rheumatology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden
Background/Purpose: It is unclear whether and to what extent different phenotypes of spondylarthritis (SpA) are associated with an increased risk of cardiovascular events such as…
Abstract Number: 1547 • 2015 ACR/ARHP Annual Meeting
Implementing an Electronic Medical Recorded-Based Clinical Decision Support Tool Did Not Improve Cardiovascular Risk Screening in Rheumatoid Arthritis Patients
Anand Kumthekar¹, Michail Alevizos², Nicole Jordan³ and Anna R. Broder⁴, ¹Medicine, Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ²Medicine, Albert Einstien College of Medicine/Jacobi Medical Center, Bronx, NY, ³Montefiore Medical Center, New York, NY, ⁴Rheumatology-Forchheimer 701N, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of death among individuals with rheumatoid arthritis (RA). The 2010 EULAR guidelines recommend annual CV risk assessment…
Abstract Number: 1787 • 2015 ACR/ARHP Annual Meeting
Innate Immunity, Arterial Inflammation and Vascular Stiffness in Patients with Systemic Lupus Erythematosus
Monica Purmalek¹, Simantini Sakhardande¹, Yenealem Temesgen-Oyelakin², Alice Fike³, Taufiq Salahuddin⁴, Balaji Natarajan⁴, Zerai Manna², Elizabeth Joyal², Sarfaraz Hasni², Nehal N. Mehta⁴ and Mariana J. Kaplan¹, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴NHLBI, National Institutes of Health, Bethesda, MD
Background/Purpose: Patients with systemic lupus erythematosus (SLE) show a striking increase in risk of atherosclerotic cardiovascular disease (CVD) not explained by Framingham risk, compared to…
Abstract Number: 2501 • 2015 ACR/ARHP Annual Meeting
Determining the Rate of Cardiovascular Risk Assessment in Patients with Rheumatoid Arthritis at Federally Qualified Outpatient Continuity Clinic – a Performance Improvement Project
Dewan Fahima¹ and Rafah Salloum², ¹Internal Medicine, Monmouth Medical Center, Long Branch, NJ, ²Rheumatology, Monmouth Medical Center, Long Branch, NJ
Background/Purpose: Studies have shown patients with rheumatoid arthritis (RA), a chronic inflammatory condition, have accelerated rate of coronary artery and cerebrovascular disease. Patients with RA,…
Abstract Number: 133 • 2015 ACR/ARHP Annual Meeting
Advocating for Rheumatoid Arthritis and Cardiovascular Health (ARCH) in a Tertiary Referral Center: A Collaborative and Systems-Based Approach to Improve Access to Care
Barbara Goldstein¹, JoAnn Zell¹, Pearlanne Zelarney², Matthew Stern², Sarah Meadows², Meg Dingae², Carmen Egidio² and Darlene Kim², ¹Medicine, National Jewish Health, Denver, CO, ²National Jewish Health, Denver, CO
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular disease (CVD) as compared to the general population. The European League Against Rheumatism…
Abstract Number: 1202 • 2015 ACR/ARHP Annual Meeting
Knowledge and Perception of Cardiovascular Disease Risk in Patients with Psoriatic Disease
Dennis Wong¹, Daniel Pereira², Sutha Shanmugarajah¹, Renise Ayearst², Dafna Gladman², Cheryl Rosen³ and Vinod Chandran², ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The prevalence of cardiovascular diseases (CVD) is higher in patients with psoriatic disease. Psoriatic disease is known to be an independent risk factor for…
Abstract Number: 1550 • 2015 ACR/ARHP Annual Meeting
Flares of Disease Activity As Risk Factor for the Occurrence of Myocardial Infarction in Patients with Rheumatoid Arthritis
Esmee Bakker¹, Pauline Geuijen², Beata Radovits¹, Delia Popa-Diaconu¹, Calin Popa¹, Elke Arts¹, Alfons A. den Broeder³ and Jaap Fransen¹, ¹Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular diseases (CVD). The underlying mechanism is partly explained by the inflammation process in both…
Abstract Number: 1788 • 2015 ACR/ARHP Annual Meeting
Lipoprotein Subfractions and Cardiovascular Disease in Systemic Lupus Erythematosus
Simantini Sakhardande¹, Monica Purmalek¹, Maureen Sampson², Yenealem Temesgen-Oyelakim³, Alice Fike⁴, Taufiq Salahuddin⁵, Balaji Natarajan⁵, Zerai Manna⁶, Elizabeth Joyal⁶, Marcus Chen⁵, Sarfaraz Hasni⁶, Nehal N. Mehta^5,7, Alan Remaley⁵ and Mariana J. Kaplan¹, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²CC/NIH, Bethesda, MD, ³Office of the Clinical Director,National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵NHLBI, National Institutes of Health, Bethesda, MD, ⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁷National Heart Lung Blood Institute, Cardiovascular and Pulmonary Division, NHLBI, National Institutes of Health, Bethesda, MD
Background/Purpose: Risk of atherosclerotic cardiovascular disease (CVD) is significantly enhanced in systemic lupus erythematosus (SLE) compared to age and gender matched controls. While this risk…
Abstract Number: 2578 • 2015 ACR/ARHP Annual Meeting
Cardiovascular Effects of Etanercept in an Animal Model of Rheumatoid Arthritis: Mechanisms Involved
Perle Totoson¹, Katy Maguin-Gaté¹, Alice Monnier², Anne Tessier², Christine Marie², Frank Verhoeven³, Clément Prati³, Daniel Wendling⁴ and Céline Demougeot¹, ¹EA 4267 FDE, FHU INCREASE, Université de Bourgogne Franche-Comté, Besançon, France, ²INSERM U1093, Université de Bourgogne Franche-Comté, Dijon, France, ³Service de Rhumatologie, CHRU J Minjoz, Besançon, France, ⁴Université de Franche-Comté, Besançon, France
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased cardiovascular (CV) morbidity and mortality secondary to endothelial dysfunction (ED). Growing evidence suggests that TNFα-inhibitors may reduce…
Abstract Number: 224 • 2015 ACR/ARHP Annual Meeting
Silent Monosodium Urate Crystals Deposits in Asymptomatic Hyperuricemia Lead to a Higher Need for Coronary Revascularization
Mariano Andrés¹, María Amparo Quintanilla², Francisca Sivera³, José Sánchez-Payá⁴, Juan M Ruiz-Nodar⁵, Eliseo Pascual^1,6 and Paloma Vela^1,6, ¹Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, ²Sección de Cardiología, Hospital General Universitario de Elda, Alicante, Spain, ³Reumatología, Hospital General Universitario de Elda, Alicante, Spain, ⁴Servicio de Medicina Preventiva, Hospital General Universitario de Alicante, Alicante, Spain, ⁵Servicio de Cardiología, Hospital General Universitario de Alicante, Alicante, Spain, ⁶Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain
Background/Purpose: Increased cardiovascular (CV) risk in gout relates to crystal-driven inflammation. In a preliminary, cross-sectional study we found that silent deposits of monosodium urate (MSU)…
Abstract Number: 1320 • 2015 ACR/ARHP Annual Meeting
Assessment of 18F-Fluoro-Deoxyglucose Uptake in the Ascending Aorta of Rheumatoid Arthritis Patients
Ayse Bag Ozbek¹, Jon Giles¹, Richard Weinberg², Mona Kinkhabwala², Afshin Zartoshti¹, Sabahat Bokhari² and Joan Bathon¹, ¹Rheumatology, Columbia University Medical Center, NY, NY, ²Cardiology, Columbia University Medical Center, NY, NY
Background/Purpose: Increased cardiovascular (CV) disease risk in RA has been attributed to traditional CV risk factors and/or to enhanced inflammation. Increased subclinical vascular inflammation has…
Abstract Number: 1553 • 2015 ACR/ARHP Annual Meeting
Effect of Drug Therapy on Net Cholesterol Efflux Capacity of HDL-Enriched Serum in Rheumatoid Arthritis
Michelle J. Ormseth¹, S. Louis Bridges Jr.², Jeffrey R. Curtis³, Joseph F. Solus⁴, Patricia Yancey⁵, MacRae F. Linton⁶, Sean Davies⁶, L Jackson Roberts II⁷, Kasey C. Vickers⁶, Valentina Kon⁶, Sergio Fazio⁸, C Michael Stein⁶ and TETRAD Investigators, ¹Department of Medicine, Division of Rheumatology, Vanderbilt University, Nashville, TN, ²Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Pharmacology, Vanderbilt University, Nashville, TN, ⁵Medicine, Vanderbilt University, Nashville, TN, ⁶Vanderbilt University, Nashville, TN, ⁷Pharmacology, Vanderbilt University, Nashville, TN, ⁸Oregon Health and Science University, Portland, OR
Background/Purpose: Patients with rheumatoid arthritis (RA) have increased coronary heart disease risk. Some RA therapies may modify this risk, but underlying mechanisms are unclear. The…
Abstract Number: 1819 • 2015 ACR/ARHP Annual Meeting
Comparison of Electrocardiographic ST-T Changes and QTc Duration in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Laura Geraldino-Pardilla¹, Yevgeniya Gartshteyn², Jon T. Giles³, Thania Perez⁴, Anca D. Askanase⁵ and Joan M. Bathon⁶, ¹Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Medicine, Columbia University, College of Physicians & Surgeons, New York, NY, ³Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁴Columbia University, College of Physicians & Surgeons, New York, NY, ⁵Department of Medicine Rhemuatology, Colombia University, New York, NY, ⁶Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Cardiovascular disease (CVD) is a leading cause of death in systemic lupus erythematosus (SLE) and in rheumatoid arthritis (RA). Longer corrected QT segments (QTc)…
Abstract Number: 2631 • 2015 ACR/ARHP Annual Meeting
Rheumatologists More Likely to Perform Tobacco Cessation Counselling in Uncontrolled Rheumatoid Arthritis Visits
Andrew Vreede¹, Katya Voelker², Joanna Wong³ and Christie M. Bartels⁴, ¹Internal Medicine, University of Wisconsin Hospitals and Clinics, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI, ³Tufts School of Medicine, Boston, MA, ⁴Medicine, Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Tobacco use is a risk factor for developing rheumatoid arthritis (RA) and a predictor of more severe disease and heightened cardiovascular disease (CVD) risk.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].